Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Swixx BioPharma - LARVOL DELTA

Combination of extracorporeal photopheresis and mogamulizumab in Sézary syndrome: effectiveness and feasibility of same-day administration (ADO 2026) - No abstract available

Cutaneous T-cell Lymphoma • Sezary Syndrome

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma. (PubMed, Blood) - "Moga-CHOP is now considered a preferable first-line treatment for these patients. Clinical Trial Identifier: jRCTs041180130."

IO biomarker • Journal • P2 data • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CCR4

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients (ASH 2024) - "Zidovudine (AZT) with Interferon-alpha has been the backbone of acute ATLL treatment for the past three decades...This backbone was combined with Venetoclax in one patient and mogamulizumab in another...We propose integrating Biktarvy and PEG-IFN as part of induction or maintenance strategies in ATLL, possibly in combination with other agents. A prospective clinical trial is being designed to evaluate the effect of PEG-IFN and Biktarvy in a larger standardized patient cohort."

Clinical • Adult T-Cell Leukemia-Lymphoma • Fatigue • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Septic Shock • CD4 • IFNA1

Mogamulizumab-Induced Tumor Lysis Syndrome in a Patient with Advanced Sézary Syndrome: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Metastases • Cutaneous T-cell Lymphoma • Oncology • Sezary Syndrome

Erythematous dorsal plaques in 6 patients with advanced T-cell lymphoma: a clinical variant of mogamulizumab-associated rash. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

New Annular, Indurated Plaques During Mogamulizumab Therapy in Cutaneous T-Cell Lymphoma: A Clinicopathologic Pitfall. (PubMed, J Cutan Pathol) - "Accurate classification requires a structured, algorithmic approach incorporating repeat biopsy, histopathologic assessment, immunophenotyping, molecular studies, and comparison with prior clinical and pathologic findings over time as well as appropriate restaging. Recognition of this diagnostic pitfall, particularly in patients with darker skin types, is essential to guide appropriate management during mogamulizumab therapy."

Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma

Side effect management under mogamulizumab: practical strategies based on clinical case studies (ADO 2026) - "Sponsored by Kyowa Kirin GmbH"

Adverse events • Case study • Clinical • Cutaneous T-cell Lymphoma

Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial. (ASCO 2025) - P2 | "The long term follow-up data from TELLOMAK study in a R/R SS population previously treated with 2 or more prior systemic therapies including mogamulizumab, confirm that lacutamab shows promising clinical activity with ORR 42.9% (95% CI 31.4-55.1) and median duration of response of 25.6 months (11.0, NE) and an overall favourable safety profile. These data support the further development of lacutamab in an effort to bring improved treatments to patients with SS."

Clinical • P2 data • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Sezary Syndrome • KIR3DL2

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL) (ASH 2022) - "In the Phase III MAVORIC trial comparing mogamulizumab to vorinostat, mogamulizumab-associated rash (MAR) was reported in 25% of patients (pts) and was more common in responders than in non-responders. The development of MAR in patients with CTCL is associated with higher rates of CR and ORR and significantly longer PFS and OS. CR/PR response in blood were associated with improved PFS. Additionally, 40% of patients who developed MAR and discontinued mogamulizumab had ongoing responses without additional systemic therapy."

IO biomarker • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CCR4

An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. (PubMed, Blood) - P2 | "Twenty-five patients (median age, 69.0) with a median of 3 prior lines of therapy were enrolled; 24 had prior mogamulizumab treatment. Grade ≥3 TEAEs included thrombocytopenia, anemia, lymphopenia, leukopenia, and neutropenia. Valemetostat demonstrated promising efficacy and tolerability in heavily pretreated patients, warranting further investigation in treating R/R ATL."

Journal • P2 data • Adult T-Cell Leukemia-Lymphoma • Alopecia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • EZH2

Industry Symposium: Kyowa Kirin GmbH Mogamulizumab in CTCL: From Evidence to Strategic Application (ADO 2026) - "Sponsored by Kyowa Kirin GmbH"

Cutaneous T-cell Lymphoma

Real-world effectiveness and safety of mogamulizumab in advanced cutaneous T-cell lymphomas: a multicenter study with clinicopathological characterization of mogamulizumab-associated rash (EADV 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • T Cell Non-Hodgkin Lymphoma

Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. (PubMed, Haematologica) - P2 | "Investigator choice chemotherapy did not result in tumor response in this trial; however, mogamulizumab treatment resulted in 11% confirmed overall response rate, with a tolerable safety profile. This trial was registered at www.clinicaltrials.gov as NCT01626664."

Clinical • Journal • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Thrombocytopenia

Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial (ASH 2023) - P2 | "Conclusion In this SS cohort from the TELLOMAK study, our data confirm that lacutamab monotherapy shows promising clinical activity in a R/R population previously treated with 2 or more prior systemic therapies including mogamulizumab, and an overall favourable safety profile. Continued evaluation of this new targeted treatment option for patients with SS is warranted."

Clinical • P2 data • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pruritus • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • KIR3DL2

Recurrent mogamulizumab-associated exanthem with varying clinical-histological patterns in Sézary syndrome with large cell transformation (ADO 2026) - No abstract available

Clinical • Cutaneous T-cell Lymphoma • Sezary Syndrome

Peginterferon Alfa-2a and Bictegravir/ Emtricitabine/Tenofovir Alafenamide in North American Adult T-Cell Leukemia/Lymphoma (NAATLL): A Preliminary Report (SOHO 2025) - "Two patients received additional therapies: venetoclax (n = 1) and mogamulizumab (n = 1). This first experience with PEG-IFNA2a and Biktarvy in ATLL demonstrates promising clinical activity, manageable toxicity, and significant virologic and hematologic responses. These results support further prospective trials of this combination in both induction and maintenance therapy for ATLL."

Clinical • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD4

Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review. (PubMed, Front Med (Lausanne)) - "Peripheral neuropathy was the defining AE of brentuximab vedotin. Mogamulizumab was distinguished by mogamulizumab-associated rash, a treatment-emergent immune reaction that closely mimics CTCL progression. Bexarotene required proactive management of hypertriglyceridemia and central hypothyroidism...A recurring challenge is distinguishing cutaneous drug toxicity from CTCL progression, underscoring the importance of therapy-specific toxicity awareness. Standardized AE reporting and patient-centered outcome measures are needed to optimize long-term care in this population."

Adverse events • Journal • Review • Cutaneous T-cell Lymphoma • Dermatology • Dyslipidemia • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Hypertriglyceridemia • Infectious Disease • Lymphoma • Mucositis • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Pain • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Mogamulizumab as a game changer in advanced CTCL (ADO 2026) - "Sponsored by Kyowa Kirin GmbH."

Metastases • Cutaneous T-cell Lymphoma

Mogamulizumab-induced tumor lysis syndrome in a patient with advanced Sézary syndrome (ADO 2026) - No abstract available

Clinical • Metastases • Cutaneous T-cell Lymphoma • Oncology • Sezary Syndrome

Preauricular plaques: a new clinical clue for the diagnosis of mogamulizumab-associated rash (ADO 2026) - No abstract available

Clinical • Genetic Disorders • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor

First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors. (PubMed, Cancer) - P1 | "KHK2455 + mogamulizumab was safe and well tolerated with manageable toxicities, and resulted in dose-dependent suppression of IDO1 activity; signals of antitumor activity were observed."

Journal • Monotherapy • P1 data • Brain Cancer • Esophageal Cancer • Glioblastoma • Oncology • Solid Tumor • CCR4

Upadacitinib as a therapeutic alternative in refractory mogamulizumab-associated cutaneous reactions: a single-center case series of 9 patients (EADV 2026) - No abstract available

Clinical

Real-world effectiveness of mogamulizumab and prognostic value of sustained response (ORR4) in mycosis fungoides and Sézary syndrome: the FIL-MOGA study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology • Sezary Syndrome

Mogamulizumab Dose Interval Extension to Every Four Weeks in Mycosis Fungoides and Sézary Syndrome: A Real-World Multicenter Experience (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology • Sezary Syndrome

Successful combination therapy of mogamulizumab together with whole-skin radiation in advanced, refractory mycosis fungoides (ADO 2026) - No abstract available

Combination therapy • Metastases • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology